Moderna Publishes Presentation on mRNA-3927 for Propionic Acidemia

• Moderna published its SSIEM 2026 presentation on mRNA-3927, an investigational treatment for propionic acidemia.
• The presentation covers more than 50 cumulative patient-years of exposure across the PARAMOUNT Part 1 and extension studies.
• Doses of 0.45, 0.6 and 0.9 mg/kg will continue to be investigated based on the totality of available evidence.
• Of 20 participants, 17 entered the extension study; two discontinued treatment, including one because of an adverse event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.